Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy

5 Aug 2024

Abstract excerpt

We describe in this review the historical evidence leading up to the concept and design of Vigil and subsequent clinical applications including safety and efficacy in a randomized, controlled Phase IIB trial. Vigil (gemogenovatucel-T) is a unique triple function targeted immunotherapy that demonstrates preclinical and clinical systemic anticancer activity. Construction of Vigil involves harvest of autologous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39101448
DOI: 10.1080/14796694.2024.2376518

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapyPMID 39101448Read ↗

Human cancer-targeted immunity via transgenic hematopoietic stem cell progenySemantic proximity Read ↗

A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generationSemantic proximity Read ↗

Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsSemantic proximity Read ↗

A Simplified Function-First Method for the Discovery and Optimization of Bispecific Immune Engaging AntibodiesSemantic proximity Read ↗

Individualised neoantigen cancer vaccine therapy.Semantic proximity Read ↗

Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer ImmunotherapySemantic proximity Read ↗

In vivo vaccination with cell line-derived whole tumor lysates – neoantigen quality, not quantity mattersSemantic proximity Read ↗

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activitySemantic proximity Read ↗

Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.Semantic proximity Read ↗

Immunotherapy of Cancer Using Systemically Delivered Gene-Modified Human T LymphocytesSemantic proximity Read ↗

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.Semantic proximity Read ↗

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.